Keryx Biopharmaceuticals Newswire

Keryx Biopharmaceuticals Newswire

Comprehensive Real-Time News Feed for Keryx Biopharmaceuticals.

Results 1 - 20 of 222 in Keryx Biopharmaceuticals

  1. Cadence Design Systems, Inc. (CDNS) Reaches $45.60 52-Week High;...Read the original story

    1 hr ago | Hill Country Times

    Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $579.42 million.

    Comment?

  2. Phosphate Binding Agents Market Opportunity Analysis and Industry Forecast Up to 2025Read the original story w/Photo

    Thursday Jan 18 | SBWire

    ... gastrointestinal tract, ultimately making it unavailable to the body for absorption. In June 2014, Keryx Biopharmaceuticals, Inc. received patent for Zerenex, a ferric citrate based phosphate binder, which will expire in 2024. The company has filed ...

    Comment?

  3. Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Keryx...Read the original story w/Photo

    Wednesday Jan 17 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendationsfor Keryx Biopharmaceuticals with our free daily email newsletter: News coverage about Keryx Biopharmaceuticals has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time.

    Comment?

  4. Keryx Biopharmaceuticals (KERX) Getting Somewhat Favorable Press Coverage, Accern ReportsRead the original story w/Photo

    Friday Jan 12 | Daily Political

    Headlines about Keryx Biopharmaceuticals have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time.

    Comment?

  5. Anemia Drugs Market Research Report - Forecast 2017-2025Read the original story w/Photo

    Friday Jan 12 | SBWire

    ... anemia in the region. Some of the key players present in global anemia drugs market are Amgen Inc., Keryx Biopharmaceuticals, Inc., GlaxoSmithKline plc, Pfizer Inc., Emmaus Medical Inc., Allergan Inc., Meda Cuonsumer Healthcare Inc., F. Hoffmann La ...

    Comment?

  6. -$0.18 EPS Expected for Keryx Biopharmaceuticals (KERX) This QuarterRead the original story w/Photo

    Thursday Jan 11 | IntersportsWire

    Wall Street analysts expect Keryx Biopharmaceuticals to post earnings of per share for the current fiscal quarter, according to Zacks Investment Research . Three analysts have issued estimates for Keryx Biopharmaceuticals' earnings.

    Comment?

  7. Brokerages Expect Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $17.17 MillionRead the original story w/Photo

    Wednesday Jan 10 | AmericanBankingNews.com

    Equities research analysts expect Keryx Biopharmaceuticals to report $17.17 million in sales for the current fiscal quarter, according to Zacks Investment Research . Three analysts have made estimates for Keryx Biopharmaceuticals' earnings.

    Comment?

  8. Zacks: Brokerages Anticipate Keryx Biopharmaceuticals (KERX) to Post -$0.19 Earnings Per ShareRead the original story w/Photo

    Monday Jan 8 | AmericanBankingNews.com

    Analysts expect Keryx Biopharmaceuticals to post earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Keryx Biopharmaceuticals' earnings, with estimates ranging from to .

    Comment?

  9. Keryx Biopharmaceuticals (KERX) Given Average Recommendation of "Hold" by BrokeragesRead the original story w/Photo

    Tuesday Jan 2 | AmericanBankingNews.com

    Shares of Keryx Biopharmaceuticals have been given a consensus rating of "Hold" by the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company.

    Comment?

  10. Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Keryx...Read the original story w/Photo

    Tuesday Jan 2 | Daily Political

    Headlines about Keryx Biopharmaceuticals have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time.

    Comment?

  11. $18.60 Million in Sales Expected for Keryx Biopharmaceuticals (KERX) This QuarterRead the original story w/Photo

    Monday Dec 25 | Daily Political

    Wall Street brokerages predict that Keryx Biopharmaceuticals will post sales of $18.60 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Keryx Biopharmaceuticals' earnings, with the lowest sales estimate coming in at $16.90 million and the highest estimate coming in at $21.98 million.

    Comment?

  12. -$0.19 EPS Expected for Keryx Biopharmaceuticals (KERX) This QuarterRead the original story w/Photo

    Saturday Dec 23 | Daily Political

    Equities analysts predict that Keryx Biopharmaceuticals will announce earnings per share of for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Keryx Biopharmaceuticals' earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  13. Financial Comparison: Keryx BiopharmaceuticalsRead the original story w/Photo

    Friday Dec 22 | IntersportsWire

    Keryx Biopharmaceuticals and Aerie Pharmaceuticals are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Keryx Biopharmaceuticals has a beta of 4.94, suggesting that its share price is 394% more volatile than the S&P 500.

    Comment?

  14. Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan's ...Read the original story w/Photo

    Friday Dec 22 | GlobeNewswire

    Keryx Biopharmaceuticals, Inc, , a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast its corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018 at 11:30 a.m. PST . In addition, the company will webcast the question & answer session immediately following its presentation at 12:00 p.m. PST .

    Comment?

  15. Engineers Gate Manager LP Acquires Shares of 14,300 Keryx BiopharmaceuticalsRead the original story w/Photo

    Dec 19, 2017 | Daily Political

    Engineers Gate Manager LP acquired a new position in shares of Keryx Biopharmaceuticals during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 14,300 shares of the biopharmaceutical company's stock, valued at approximately $102,000.

    Comment?

  16. Keryx Biopharmaceuticals (KERX) Short Interest Up 6.9% in NovemberRead the original story w/Photo

    Dec 18, 2017 | Daily Political

    Keryx Biopharmaceuticals saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 21,658,433 shares, an increase of 6.9% from the November 15th total of 20,254,558 shares.

    Comment?

  17. BioVectra, Keryx Enter Supply Agreement for Kidney DiseaseRead the original story w/Photo

    Dec 14, 2017 | Contract Pharma Breaking News

    BioVectra Inc. has announced a long-term supply agreement with Keryx Biopharmaceuticals to manufacture Ferric Citrate, the active pharmaceutical ingredient in Auryxia tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra brings over 45 years of contract development and manufacturing experience to the partnership.

    Comment?

  18. Phosphate Binding Agents Market to Witness an Outstanding Growth by 2025Read the original story w/Photo

    Dec 11, 2017 | SBWire

    ... gastrointestinal tract, ultimately making it unavailable to the body for absorption. In June 2014, Keryx Biopharmaceuticals, Inc. received patent for Zerenex, a ferric citrate based phosphate binder, which will expire in 2024. The company has filed ...

    Comment?

  19. Keryx Biopharmaceuticals (KERX) Receives $7.00 Average PT from BrokeragesRead the original story w/Photo

    Dec 11, 2017 | The Breeze

    Shares of Keryx Biopharmaceuticals have earned a consensus recommendation of "Hold" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has issued a buy recommendation on the company.

    Comment?

  20. Keryx Biopharmaceuticals (KERX) Given Average Rating of "Hold" by BrokeragesRead the original story w/Photo

    Dec 8, 2017 | IntersportsWire

    Shares of Keryx Biopharmaceuticals have received an average rating of "Hold" from the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company.

    Comment?